Compare CAPR & EZPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | EZPW |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 1991 |
| Metric | CAPR | EZPW |
|---|---|---|
| Price | $22.51 | $24.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $41.38 | $24.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 03-18-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.86 |
| EPS | N/A | ★ 1.57 |
| Revenue | $11,130,509.00 | ★ $1,336,129,000.00 |
| Revenue This Year | N/A | $12.38 |
| Revenue Next Year | $17,308.50 | $9.01 |
| P/E Ratio | ★ N/A | $15.46 |
| Revenue Growth | N/A | ★ 13.06 |
| 52 Week Low | $4.30 | $12.85 |
| 52 Week High | $40.37 | $26.35 |
| Indicator | CAPR | EZPW |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 62.22 |
| Support Level | $23.23 | $24.57 |
| Resistance Level | $25.45 | $25.50 |
| Average True Range (ATR) | 1.39 | 0.92 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 64.01 | 60.50 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.